What are the benefits of using angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure?
Studies have shown that angiotensin-converting-enzyme (ACE) inhibitors can reduce the risk of cardiovascular morbidity and mortality in patients with stable vascular disease without left ventricular systolic dysfunction or heart failure. Specifically, the Losartan Intervention For Endpoint reduction in hypertension study (LIFE), The EUROPA study, The PROGRESS Collaborative Group study, The telmisartan study, The Heart Outcomes Prevention Evaluation (HOPE) Study, and The ALLHAT study have all found that ACE inhibitors can reduce the risk of stroke, heart attack, and other cardiovascular events. Additionally, ACE inhibitors have been found to reduce the risk of death in patients with diabetes. Overall, the use of ACE inhibitors in patients with stable vascular disease can be beneficial in reducing the risk of cardiovascular morbidity and mortality.  